Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma | MicrobiomeTrials← Back to trialsNCT03011814
Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma
RecruitingPHASE1, PHASE2INTERVENTIONAL
Trial Details
Start: 2017-03-08Est. Completion: 2030-04-14
Enrollment target: 78 participants Locations- City of Hope Medical Center, Duarte, California, United States
- Memorial Sloan-Kettering Cancer Center, New York, New York, United States
- Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States
- M D Anderson Cancer Center, Houston, Texas, United States
Other microbiome trials you might be interested in
Folliculotropic Mycosis FungoidesPrimary Cutaneous T-Cell Non-Hodgkin LymphomaSezary SyndromeStage IB Mycosis Fungoides and Sezary Syndrome AJCC v8Stage II Mycosis Fungoides and Sezary Syndrome AJCC v8Stage IIA Mycosis Fungoides and Sezary Syndrome AJCC v8Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v8Transformed Mycosis Fungoides
This phase II trial studies the effect of extracorporeal photopheresis (ECP) and mogamulizumab in treating patients with…
Scottsdale, United StatesEst. completion Jun 15, 2028
Recruiting
Chronic Spontaneous Urticaria (CSU)Hidradenitis Suppurativa (HS)Psoriasis (PsO)Atopic Dermatitis (AD)CTCL/ Mycosis Fungoides
The goal of this observational study is to comprehensively profile six immune-mediated inflammatory diseases, including …
Nijmegen, NetherlandsEst. completion Dec 31, 2029